Blood Advances

Article	Citations
13q12.2 deletions and FLT3 overexpression in acute leukemias	520
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML	319
Allogeneic hematopoietic cell transplantation for adult metachromatic leukodystrophy: a case series	236
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses	137
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia	137
Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia	135
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia	124
A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis	107
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials	105
Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia	102
Audit of B-cell Cancer Genes	101
Characterization of the Phenotypic Consequences of the Duffy-Null Genotype	100
Systemic Mastocytosis: Current Status and Challenges in 2024	100
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.	90
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response	84
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs	83
Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels	81
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	77
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	77
Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations	76
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	76
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	75
Commentary on the ASH 2020 guidelines on cognitive screening and intervention in sickle cell disease	73
A transcriptome analysis of basal and stimulated VWF release from endothelial cells derived from patients with type 1 VWD	69
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	68

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD + acute myeloid leukemia	67
NUP98 is rearranged in 5.0% of adult East Asian patients with AML	66
Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression	66
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis	64
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models	63
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R	62
A new murineRpl5(uL18) mutation provides a unique model of variably penetrant Diamond-Blackfan anemia	62
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab	61
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT	61
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	60
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	60
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia	60
Elucidating parasite and host-cell factors enabling Babesia infection in sickle red cells under hypoxic/hyperoxic conditions	60
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience	60
Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR inRUNX1deficiency	59
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia	59
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up	58
A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale	57
Histidine-rich glycoprotein attenuates catheter thrombosis	57
Peripheral megakaryocytes sound the alarm in COVID-19	56
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel	56
In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation	55
Systematic review of outcome reporting in studies of SCD and pregnancy: marked heterogeneity hinders meaningful data synthesis	54
Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome	54
Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective	54
Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report	54
pH-dependent conformation of multimeric von Willebrand factor	54
Transfusion therapy for sickle cell disease: what’s new?	54
Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis	53
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study	53
A predictive model for bone marrow disease in cytopenia based on noninvasive procedures	52
A sweet deal: blocking NMDAR for safer t-PA in diabetes	52
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial	52
Pediatric transplant–associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy	52
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19	51
CCR8 is a new therapeutic target in cutaneous T-cell lymphomas	50
Essential role of glycoprotein Ibα in platelet activation	50
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas	50
Evans syndrome in adults: an observational multicenter study	49
Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation	49
Search for AL amyloidosis risk factors using Mendelian randomization	49
HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia	49
Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease	47
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy	47
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	46
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML	46
Haptoglobin 1 allele predicts higher serum haptoglobin concentration and lower multiorgan failure risk in sickle cell disease	46
SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow	45
Challenges in applying diagnostic criteria for systemic mastocytosis	45
Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma	45

Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model	45
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm	45
Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features	45
Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT	45
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience	45
Telomerase-targeted therapies in myeloid malignancies	45
An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia	45
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia	44
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question	44
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	44
A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD	44
Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis	44
Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging	43
Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice	43
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia	43
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera	43
Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A	43
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia	43
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists	43
Single-cell immune profiling reveals a developmentally distinct CD4+ GM-CSF+ T-cell lineage that induces GI tract GVHD	42
A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting	42
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms	42
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	42
Addressing and overcoming disparities in GVHD	42
Loss of early myeloid donor cell engraftment into the central nervous system with nonmyeloablative conditioning	42
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia	42
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	41
External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort	41
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	41
Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL	41
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL	41
Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations	41
Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome	41
R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation	40
Anti-HK antibody reveals critical roles of a 20-residue HK region for Aβ-induced plasma contact system activation	40
On a collision course: SARS-CoV-2 variants and CAR T cells	40
Platelet proteomic profiling in sitosterolemia suggests thrombocytopenia is driven by lipid disorder and not platelet aberrations	40
R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling	39
Restriction of HIV-1 infection in sickle cell trait	39
Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis	39
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	39
EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome	38
Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors	38
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia	38
Adenylate kinase 2 expression and addiction in T-ALL	38
The fate of mitochondria during platelet activation	37
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	37
Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies	37
Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes	37
Applying CRISPR-Cas9 screens to dissect hematological malignancies	37
Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy	37
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted	36
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease	36
Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells	36
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry	35
Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity	35
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study	35
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma	35
A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation	34
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders	34
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile	34
Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS	34
O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies	34
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies	34
Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study	34
Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer	33
Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels	33
Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice	33
Deletion of pyruvate dehydrogenase kinases reduces susceptibility to deep vein thrombosis in mice	33
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura	33
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial	33
CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia	33
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type	33
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen	33
Elevated RIPK3 correlates with disease burden in myelofibrosis	33
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma	32
Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia	32
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia	32
A patient with a germlineGATA2mutation and primary myelofibrosis	32
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype	32

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	32
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	32
IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis	32
Deregulated expression of circular RNAs in acute myeloid leukemia	32
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes	32
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study	31
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study	31
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen	31
Fibrin protofibril packing and clot stability are enhanced by extended knob-hole interactions and catch-slip bonds	31
Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity	31
Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study	31
Autologous transplant and second malignancies in MM	31
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	31
Altered platelet-megakaryocyte endocytosis and trafficking of albumin and fibrinogen in RUNX1 haplodeficiency	31
Vascular surgery patients with elevated neutrophil-to-lymphocyte ratios have downregulated neutrophil complement RNA expression	31
Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis	30
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study	30
Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease	30
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	30
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS	29
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia	29
Follicular lymphoma and macrophages: impact of approved and novel therapies	29
VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis	29
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	29
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD	29
A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome	29
GATA2 deficiency phenotype associated with tandem duplication of GATA2 and overexpression of GATA2-AS1	29
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy	29
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis	29
Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα	29
CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesis	28
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML	28
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis	28
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma	28
TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy	28
Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant	28
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma	28
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma	28
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)	28
Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice	28
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma	28
Hematologic complications with age in Shwachman-Diamond syndrome	28
Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome	28
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease	27
Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection	27
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	27
Characteristics of Upper and Lower Extremity Deep Vein Thrombosis and Predictors of Post-Thrombotic Syndrome in Children	27
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma	27
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy	27
DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices	27
Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques	27
Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing	27
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis	26
Genomics of PDGFR-rearranged hypereosinophilic syndrome	26
Gaps during pediatric to adult care transfer escalate acute resource utilization in sickle cell disease	26
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies	26
Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients	26
Lasting shift in the gut microbiota in patients with acute myeloid leukemia	26
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	26
A mouse model characterizes the roles of ZIP8 in systemic iron recycling and lung inflammation and infection	26
Nbeal2 Knockout Mice Are Not Protected Against Hypoxia-Induced Pulmonary Vascular Remodeling and Pulmonary Hypertension	26
HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma	26
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia	26
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies	26
Management of iron deficiency in women in Scotland	26
Steroid tapering after GVHD Rx: not too fast, not too slow	26
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	26
Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia	26
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure?	26
Impaired formation of neutrophil extracellular traps in patients with MDS	26
Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function	25
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study	25
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells	25
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML	25
ADP: the missing link between thrombosis and hemolysis	25
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy	25
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes	25
Platelets as drivers of ischemia/reperfusion injury after stroke	25
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	25
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	25
RNA-seq–based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia	25
Longitudinal plasma proteomics in CAR T–cell therapy patients implicates neutrophils and NETosis in the genesis of CRS	25
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis	25
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ	25
Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia	25
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	25
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?	25
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation	25
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia	25
Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma	25
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma	25
TheCADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11	25
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence	25
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial	25
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	24